SHPH (Shuttle Pharmaceuticals Holdings) Short-Term Debt: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHPH Shuttle Pharmaceuticals Holdings Inc SHPH
24 GF Score
Price $4.16
! 1 Warning Sign
View Full Analysis

What is Shuttle Pharmaceuticals Holdings Short-Term Debt?

Shuttle Pharmaceuticals Holdings SHPH +38.21% 24 Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates SHPH with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.

Shuttle Pharmaceuticals Holdings's Short-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Shuttle Pharmaceuticals Holdings's quarterly Short-Term Debt declined from Sep. 2025 ($0.42 Mil) to Dec. 2025 ($0.00 Mil) but then stayed the same from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Shuttle Pharmaceuticals Holdings's annual Short-Term Debt increased from Dec. 2023 ($0.60 Mil) to Dec. 2024 ($0.87 Mil) but then declined from Dec. 2024 ($0.87 Mil) to Dec. 2025 ($0.00 Mil).

Shuttle Pharmaceuticals Holdings Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Shuttle Pharmaceuticals Holdings Short-Term Debt Related Terms

Shuttle Pharmaceuticals Holdings Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Shuttle Pharmaceuticals Holdings's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shuttle Pharmaceuticals Holdings Short-Term Debt Chart

Shuttle Pharmaceuticals Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.85 0.69 0.60 0.87 0.00

Shuttle Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 0.45 0.42 0.00 0.00
SHPH
24GF Score
Shuttle Pharmaceuticals Holdings Inc SHPH
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Shuttle Pharmaceuticals Holdings (SHPH) has a Short-Term Debt of $0.00 Mil as of Mar. 2026.
Is Shuttle Pharmaceuticals Holdings' Short-Term Debt too high?
Shuttle Pharmaceuticals Holdings' current Short-Term Debt is $0.00 Mil. Overall, Shuttle Pharmaceuticals Holdings has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Shuttle Pharmaceuticals Holdings' Short-Term Debt compare to UPC and CBIH?
Shuttle Pharmaceuticals Holdings' Short-Term Debt of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Shuttle Pharmaceuticals Holdings's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shuttle Pharmaceuticals Holdings stock overvalued right now?
Shuttle Pharmaceuticals Holdings (SHPH) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Shuttle Pharmaceuticals Holdings' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Shuttle Pharmaceuticals Holdings (SHPH), the current Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shuttle Pharmaceuticals Holdings Business Description

Address 401 Professional Drive, Suite 260, Gaithersburg, MD, USA, 20879
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
24GF Score

Get the complete analysis for SHPH

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.16
Price